A nice and clinically very relevant example (for a manuscript) might be FGFR2 fusions (in cholangiocarcinoma).
They come in several different flavors including fusions leading to a loss of regulatory elements.
Complementing promotor switches and chimeric proteins.
From Albrecht Stenzinger: